WO1998048790A1 - Utilisation de la genisteine et de composes associes pour traiter certains etats lies aux hormones sexuelles - Google Patents

Utilisation de la genisteine et de composes associes pour traiter certains etats lies aux hormones sexuelles Download PDF

Info

Publication number
WO1998048790A1
WO1998048790A1 PCT/US1998/008484 US9808484W WO9848790A1 WO 1998048790 A1 WO1998048790 A1 WO 1998048790A1 US 9808484 W US9808484 W US 9808484W WO 9848790 A1 WO9848790 A1 WO 9848790A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
tissue
growth
genistein
prostate
Prior art date
Application number
PCT/US1998/008484
Other languages
English (en)
Inventor
Dusan Miljkovic
Jack Geller
Gordana Olbina
Original Assignee
Anticancer, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anticancer, Inc. filed Critical Anticancer, Inc.
Priority to AU71657/98A priority Critical patent/AU7165798A/en
Publication of WO1998048790A1 publication Critical patent/WO1998048790A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé permettant de moduler la croissance des tissus et des cellules. Le procédé consiste à mettre en contact une cellule ou un tissu avec la génistéine, ou avec d'autres isoflavinoïdes ou dérivés de ces composés, qui peuvent éventuellement être couplés à une fraction ciblant une cellule ou un tissu particulier. Le procédé de l'invention est particulièrement utile pour le traitement du cancer de la prostate, de l'hypertrophie bénigne de la prostate, du cancer du sein, et de l'alopécie androgénique.
PCT/US1998/008484 1997-04-28 1998-04-28 Utilisation de la genisteine et de composes associes pour traiter certains etats lies aux hormones sexuelles WO1998048790A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU71657/98A AU7165798A (en) 1997-04-28 1998-04-28 Use of genistein and related compounds to treat certain sex hormone related conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84854097A 1997-04-28 1997-04-28
US08/848,540 1997-04-28

Publications (1)

Publication Number Publication Date
WO1998048790A1 true WO1998048790A1 (fr) 1998-11-05

Family

ID=25303571

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/008484 WO1998048790A1 (fr) 1997-04-28 1998-04-28 Utilisation de la genisteine et de composes associes pour traiter certains etats lies aux hormones sexuelles

Country Status (2)

Country Link
AU (1) AU7165798A (fr)
WO (1) WO1998048790A1 (fr)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1027045A1 (fr) * 1997-10-31 2000-08-16 Arch Development Corporation Procedes et compositions pour reguler l'activite de la 5-alpha-reductase
EP1047420A1 (fr) * 1998-01-20 2000-11-02 HANDELMAN, Joseph H. Modulation de la croissance des poils
WO2001017986A1 (fr) * 1999-09-06 2001-03-15 Novogen Research Pty Ltd Compositions et methodes therapeutiques mettant en jeu des isoflavones et des analogues d'isoflavones
GB2361642A (en) * 2000-10-24 2001-10-31 Karobio Ab Estrogen receptor beta (ERbeta) agonists for use in cancer treatment
WO2002081491A2 (fr) * 2001-04-09 2002-10-17 Instytut Farmaceutyczny Nouveaux derives de genisteine et preparations pharmaceutiques les contenant
WO2002092129A2 (fr) * 2001-05-14 2002-11-21 Astrazeneca Ab Combinaison pharmaceutique
US6599536B1 (en) 1998-03-26 2003-07-29 Novogen Research Pty Ltd Therapy of estrogen-associated disorders
WO2003075943A2 (fr) * 2002-03-06 2003-09-18 The Medical Research And Education Trust Compositions d'extrait botanique et procedes d'utilisation
US7008649B2 (en) 1998-12-07 2006-03-07 Ecosmart Techonlogies, Inc. Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
JP2006508942A (ja) * 2002-10-29 2006-03-16 コロラド　ステート　ユニバーシティー　リサーチ　ファウンデーション アンドロゲンによって仲介される疾患を治療するためのエクオールの使用
US7033621B1 (en) 1997-04-28 2006-04-25 Novogen, Inc. Isoflavone compositions produced from legumes
EP1808172A2 (fr) * 2002-03-06 2007-07-18 The Medical Research and Education Trust Compostions à base d'extraits botaniques et procédés d'utilisation
US7312344B2 (en) 2001-03-08 2007-12-25 Novogen Research Pty Limited Dimeric isoflavones
US7396855B2 (en) 2002-07-24 2008-07-08 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
WO2009026657A1 (fr) * 2007-08-29 2009-03-05 The University Of Sydney Agonistes flavonoïdes de ppar
US20090124569A1 (en) * 2007-10-12 2009-05-14 Northwestern University Inhibition and treatment of prostate cancer metastasis
WO2011053571A1 (fr) * 2009-10-26 2011-05-05 University Of Southern California Préparations phytoestrogéniques pour l'atténuation ou la prévention de la chute des cheveux
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
US8269011B2 (en) 2007-06-06 2012-09-18 Otsuka Pharmaceutical Co., Ltd. Quinolone compound and pharmaceutical composition
US8304546B2 (en) 2008-12-05 2012-11-06 Otsuka Pharmaceutical Co., Ltd. Quinolone compound and pharmaceutical composition
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
CN113214211A (zh) * 2021-04-23 2021-08-06 广东药科大学 一种提取自牡丹皮炭的化合物及其制备方法和制药用途

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61246124A (ja) * 1985-04-24 1986-11-01 Yamanouchi Pharmaceut Co Ltd 制癌剤
JPH0196124A (ja) * 1987-10-07 1989-04-14 Fujirebio Inc 制癌剤
JPH0196126A (ja) * 1987-10-08 1989-04-14 Kao Corp ５α−リダクターゼ阻害剤
WO1993023069A1 (fr) * 1992-05-19 1993-11-25 Graham Edmund Kelly Complements benefiques pour la sante, contenant des phyto-×strogenes, des analogues ou des metabolites de ceux-ci
WO1996006116A1 (fr) * 1994-08-19 1996-02-29 Regents Of The University Of Minnesota Immunoconjugues a base d'inhibiteurs de la tyrosine kinase
DE4432947A1 (de) * 1994-09-16 1996-03-21 New Standard Gmbh Mittel zur Behandlung der Haut
WO1996039832A1 (fr) * 1995-06-07 1996-12-19 Kung Patrick C Composes et procedes visant a stimuler la pousse des cheveux
WO1997029779A2 (fr) * 1996-02-16 1997-08-21 Regents Of The University Of Minnesota Conjugues de egf-genisteine pour le traitement du cancer
WO1998008503A1 (fr) * 1996-08-30 1998-03-05 Novogen Research Pty. Ltd. Procedes therapeutiques et compositions integrant des isoflavones

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61246124A (ja) * 1985-04-24 1986-11-01 Yamanouchi Pharmaceut Co Ltd 制癌剤
JPH0196124A (ja) * 1987-10-07 1989-04-14 Fujirebio Inc 制癌剤
JPH0196126A (ja) * 1987-10-08 1989-04-14 Kao Corp ５α−リダクターゼ阻害剤
WO1993023069A1 (fr) * 1992-05-19 1993-11-25 Graham Edmund Kelly Complements benefiques pour la sante, contenant des phyto-×strogenes, des analogues ou des metabolites de ceux-ci
WO1996006116A1 (fr) * 1994-08-19 1996-02-29 Regents Of The University Of Minnesota Immunoconjugues a base d'inhibiteurs de la tyrosine kinase
DE4432947A1 (de) * 1994-09-16 1996-03-21 New Standard Gmbh Mittel zur Behandlung der Haut
WO1996039832A1 (fr) * 1995-06-07 1996-12-19 Kung Patrick C Composes et procedes visant a stimuler la pousse des cheveux
WO1997029779A2 (fr) * 1996-02-16 1997-08-21 Regents Of The University Of Minnesota Conjugues de egf-genisteine pour le traitement du cancer
WO1998008503A1 (fr) * 1996-08-30 1998-03-05 Novogen Research Pty. Ltd. Procedes therapeutiques et compositions integrant des isoflavones

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
A.I. CONSTANTINOU ET AL.: "INHIBITION OF N-METHYL-N-NITROSOUREA-INDUCED MAMMARY TUMORS IN RATS BY THE SOYBEAN ISOFLAVONES", ANTICANCER RESEARCH, vol. 16, no. 6A, 1996, pages 3293 - 3298, XP002077084 *
CHEMICAL ABSTRACTS, vol. 111, no. 21, 20 November 1989, Columbus, Ohio, US; abstract no. 187601, "ANTICANCER AGENTS CONTAINING FLAVONOIDS" *
DATABASE WPI Section Ch Week 8650, Derwent World Patents Index; Class B02, AN 86-329435, XP002077087 *
DATABASE WPI Section Ch Week 8921, Derwent World Patents Index; Class B02, AN 89-155042, XP002077086 *
DATABASE WPI Week 8921, Derwent World Patents Index; AN 89-155044 *
G. PETERSON ET AL.: "GENISTEIN INHIBITS BOTH ESTROGEN AND GROWTH FACTOR-STIMULATED PROLIFERATION OF HUMAN BREAST CANCER", CELL GROWTH AND DIFFERENTIATION, vol. 7, no. 10, 1996, pages 1345 - 1351, XP002077083 *
J. GELLER ET AL.: "GENISTEIN INHIBITS THE GROWTH OF HUMAN-PATIENT BPH AND PROSTATE CANCER IN HISTOCULTURE", PROSTATE, vol. 34, no. 2, February 1998 (1998-02-01), pages 75 - 79, XP002077078 *
J.F. SANTIBANEZ ET AL.: "GENISTEIN INHIBITS PROLIFERATION AND IN VITRO INVASIVE POTENTIAL OF HUMAN PROSTATIC CANCER CELL LINES", ANTICANCER RESEARCH, vol. 17, no. 2A, March 1997 (1997-03-01), pages 1199 - 1204, XP002077081 *
M.C. BOSLAND ET AL.: "INHIBITION OF HUMAN PROSTATE CANCER CELL PROLIFERATION BY GENISTEIN", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 38, March 1997 (1997-03-01), pages 262, XP002077080 *
PATENT ABSTRACTS OF JAPAN vol. 013, no. 308 (C - 617) 14 July 1989 (1989-07-14) *
S. BARNES ET AL.: "POTENTIAL ROLE OF DIETARY ISOFLAVONES IN THE PREVENTION OF CANCER", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, vol. 354, 1994, pages 135 - 147, XP002077082 *
Y. WANG ET AL.: "SOY ISOFLAVONES DECREASE THE HIGH-FAT GROWTH OF HUMAN PROSTATE CANCER: RESULTS OF A IN VITRO AND ANIMAL STUDIES", THE JOURNAL OF UROLOGY, vol. 153, no. S4, 1995, pages 269A, XP002077079 *

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033621B1 (en) 1997-04-28 2006-04-25 Novogen, Inc. Isoflavone compositions produced from legumes
EP1027045A4 (fr) * 1997-10-31 2004-12-08 Arch Dev Corp Procedes et compositions pour reguler l'activite de la 5-alpha-reductase
EP1027045A1 (fr) * 1997-10-31 2000-08-16 Arch Development Corporation Procedes et compositions pour reguler l'activite de la 5-alpha-reductase
EP1047420A1 (fr) * 1998-01-20 2000-11-02 HANDELMAN, Joseph H. Modulation de la croissance des poils
EP1047420B1 (fr) * 1998-01-20 2007-04-11 The Gillette Company Modulation de la croissance des poils
US6599536B1 (en) 1998-03-26 2003-07-29 Novogen Research Pty Ltd Therapy of estrogen-associated disorders
US7291650B2 (en) 1998-12-07 2007-11-06 Ecosmart Technologies, Inc. Cancer treatment composition and method using natural plant essential oils
US7008649B2 (en) 1998-12-07 2006-03-07 Ecosmart Techonlogies, Inc. Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
WO2001017986A1 (fr) * 1999-09-06 2001-03-15 Novogen Research Pty Ltd Compositions et methodes therapeutiques mettant en jeu des isoflavones et des analogues d'isoflavones
JP2003508526A (ja) * 1999-09-06 2003-03-04 ノボゲン リサーチ ピーティーワイ リミテッド イソフラボンおよびその類縁体を含む組成物および治療的方法
GB2361642A (en) * 2000-10-24 2001-10-31 Karobio Ab Estrogen receptor beta (ERbeta) agonists for use in cancer treatment
US7312344B2 (en) 2001-03-08 2007-12-25 Novogen Research Pty Limited Dimeric isoflavones
WO2002081491A3 (fr) * 2001-04-09 2004-02-26 Inst Farmaceutyczny Nouveaux derives de genisteine et preparations pharmaceutiques les contenant
WO2002081491A2 (fr) * 2001-04-09 2002-10-17 Instytut Farmaceutyczny Nouveaux derives de genisteine et preparations pharmaceutiques les contenant
WO2002092129A3 (fr) * 2001-05-14 2003-02-27 Astrazeneca Ab Combinaison pharmaceutique
WO2002092129A2 (fr) * 2001-05-14 2002-11-21 Astrazeneca Ab Combinaison pharmaceutique
WO2003075943A3 (fr) * 2002-03-06 2004-04-22 Sophie Chen Ph D Compositions d'extrait botanique et procedes d'utilisation
WO2003075943A2 (fr) * 2002-03-06 2003-09-18 The Medical Research And Education Trust Compositions d'extrait botanique et procedes d'utilisation
EP1808172A3 (fr) * 2002-03-06 2010-05-26 Activephyto Technologies Limited Compostions à base d'extraits botaniques et procédés d'utilisation
EP1808172A2 (fr) * 2002-03-06 2007-07-18 The Medical Research and Education Trust Compostions à base d'extraits botaniques et procédés d'utilisation
US7960432B2 (en) 2002-07-24 2011-06-14 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US8048913B2 (en) 2002-07-24 2011-11-01 Australian Health & Nutrition Assoc. Ltd. Compositions and products containing S-equol, and methods for their making
US9408824B2 (en) 2002-07-24 2016-08-09 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US9173866B2 (en) 2002-07-24 2015-11-03 Children's Hospital Medical Center Compositions and products containing R-equol, and methods for their making
US9018247B2 (en) 2002-07-24 2015-04-28 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
US7396855B2 (en) 2002-07-24 2008-07-08 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
EP1569636A4 (fr) * 2002-10-29 2007-07-04 Univ Colorado State Res Found Utilisation d'equol dans le traitement de maladies d'origine androgenique
JP2012021005A (ja) * 2002-10-29 2012-02-02 Colorado State Univ Research Foundation アンドロゲンによって仲介される疾患を治療するためのエクオールの使用
JP4889944B2 (ja) * 2002-10-29 2012-03-07 コロラド ステート ユニバーシティー リサーチ ファウンデーション アンドロゲンによって仲介される疾患を治療するためのエクオールの使用
US8153684B2 (en) 2002-10-29 2012-04-10 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
US9089547B2 (en) 2002-10-29 2015-07-28 Brigham Young University Use of equol for treating androgen mediated diseases
AU2003286781B2 (en) * 2002-10-29 2009-05-21 Brigham Young University Use of equol for treating androgen mediated diseases
US10111855B2 (en) 2002-10-29 2018-10-30 Brigham Young University Use of equol for treating androgen mediated diseases
JP2006508942A (ja) * 2002-10-29 2006-03-16 コロラド　ステート　ユニバーシティー　リサーチ　ファウンデーション アンドロゲンによって仲介される疾患を治療するためのエクオールの使用
US8450364B2 (en) 2002-10-29 2013-05-28 Brigham Young University Use of equol for treating androgen mediated diseases
US9889116B2 (en) 2002-10-29 2018-02-13 Bringham Young University Use of equol for treating androgen mediated diseases
US9408825B2 (en) 2002-10-29 2016-08-09 Brigham Young University Use of equol for treating androgen mediated diseases
US8642619B2 (en) 2007-06-06 2014-02-04 Otsuka Pharmaceutical Co., Ltd. Quinolone compound and pharmaceutical composition
US8269011B2 (en) 2007-06-06 2012-09-18 Otsuka Pharmaceutical Co., Ltd. Quinolone compound and pharmaceutical composition
US9403773B2 (en) 2007-06-06 2016-08-02 Otsuka Pharmaceutical Co., Ltd. Quinolone compound and pharmaceutical composition
US9045464B2 (en) 2007-06-06 2015-06-02 Otsuka Pharmaceutical Co., Ltd. Quinolone compound and pharmaceutical composition
US8354126B1 (en) 2007-06-25 2013-01-15 OncoNatural Solutions, Inc. Composition for prostate health
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
WO2009026657A1 (fr) * 2007-08-29 2009-03-05 The University Of Sydney Agonistes flavonoïdes de ppar
US20090124569A1 (en) * 2007-10-12 2009-05-14 Northwestern University Inhibition and treatment of prostate cancer metastasis
US9018229B2 (en) 2008-12-05 2015-04-28 Otsuka Pharmaceutical Co., Ltd. Quinolone compound and pharmaceutical composition
USRE45108E1 (en) 2008-12-05 2014-09-02 Otsuka Pharmaceutical Co., Ltd. Quinolone compound and pharmaceutical composition
US8592593B2 (en) 2008-12-05 2013-11-26 Otsuka Pharmaceutical Co., Ltd. Quinolone compound and pharmaceutical composition
US8304546B2 (en) 2008-12-05 2012-11-06 Otsuka Pharmaceutical Co., Ltd. Quinolone compound and pharmaceutical composition
WO2011053571A1 (fr) * 2009-10-26 2011-05-05 University Of Southern California Préparations phytoestrogéniques pour l'atténuation ou la prévention de la chute des cheveux
CN113214211A (zh) * 2021-04-23 2021-08-06 广东药科大学 一种提取自牡丹皮炭的化合物及其制备方法和制药用途
CN113214211B (zh) * 2021-04-23 2022-04-22 广东药科大学 一种提取自牡丹皮炭的化合物及其制备方法和制药用途

Also Published As

Publication number Publication date
AU7165798A (en) 1998-11-24

Similar Documents

Publication Publication Date Title
WO1998048790A1 (fr) Utilisation de la genisteine et de composes associes pour traiter certains etats lies aux hormones sexuelles
Begam et al. Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review
EP0615448B1 (fr) Inhibiteurs de l'activite des steroides sexuels
US6004558A (en) Methods for treating cancer with legume plant extracts
JP3581802B2 (ja) ステロイドスルファターゼインヒビター
Sfakianos et al. Intestinal uptake and biliary excretion of the isoflavone genistein in rats
JP4949982B2 (ja) エストロンスルファターゼインヒビターとしての非ステロイド多環式環スルファメート誘導体、それらの調製および使用
US6642397B1 (en) Steroid sulphatase inhibitors
EP1063990B1 (fr) Extrait enrichi en biochanine pour le traitement de troubles lies aux oestrogenes
Schleicher et al. The inhibitory effect of genistein on the growth and metastasis of a transplantable rat accessory sex gland carcinoma
KR101403893B1 (ko) 4,17β-디히드록시안드로스트-4-엔-3-온에 대한 신규한 용도들
KR100270432B1 (ko) 성스테로이드활성억제용에스트로겐핵유도체
KR19980702414A (ko) 벤조피란 함유 화합물 및 이들의 사용방법
US6476011B1 (en) Methods for introducing an estrogenic compound
Vassilomanolakis et al. A phase II study of flutamide in ovarian cancer
CN109152750A (zh) 用于增殖性疾病的组合疗法
US20050096381A1 (en) Derivatives of isoflavones
JPWO2004035089A1 (ja) ホルモン依存性癌の治療剤
WO2006085330A2 (fr) Utilisation d'inhibiteurs de la tyrosine kinase pour le traitement de leiomyomes
WO2005037816A1 (fr) Utilisation de 8-prenylnaringenine pour un traitement hormonal substitutif
JPH08165238A (ja) エストロゲン作用剤
US20020128243A1 (en) Steroid sulphatase inhibitors
Poirier et al. Chemical synthesis, plasmatic concentration and antisulfatase activity in mice and rats of a tetrahydroisoquinoline derivative
AU681338C (en) Sex steroid activity inhibitors
US20070021624A1 (en) Steroid sulphatase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998547262

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA